Burns McClellan handles US media for the IPO of Vaccitech, the British biopharmaceutical company that owns the technology behind AstraZeneca’s COVID-19 vaccine.
Vaccitech on April 29 priced the IPO shares at $17 each, which valued the IPO at $579M. The shares trade on the NASDAQ.
Vaccitech was co-founded by University of Oxford scientists Sarah Gilbert and Adrian Hill and has received backing from Google Ventures and Gilead Sciences.
It will receive 1.4 percent of net revenues from the AstraZeneca COVID-19 vaccine, after it is sold for profit following the end of the pandemic, according to the Financial Times.
Founded in 1988 by Lisa Burns, New York-based Burns McClellan bills itself as an independent IR/financial PR firm serving the life sciences market.
It has Ryo Imai and Robeert Flamm working the Vaccitech IPO. London’s Scius Communications (Katja Stout) is working the European media.